CapsoVision (CV) Q3 2025 earnings summary

Executive summary

• Q3 2025 revenue grew 19% year-over-year to $3.5 million, driven by increased CapsoCam Plus sales and expanded U.S. and international market penetration.

• New account generation increased 31% year-over-year, with over 151,000 patients having used CapsoCam Plus as of September 30, 2025.

• Expanded pipeline with FDA submission for AI-enabled CapsoCam Plus and Breakthrough Device Designation for pancreatic cancer screening.

• Entered a development agreement with Canon for next-generation CMOS imaging sensors to enhance future capsule endoscopes.

• Completed IPO in July 2025, raising $23.4 million in net proceeds, converting all preferred stock to common stock, and appointing a new SVP of Finance.

Financial highlights

• Q3 2025 revenue: $3.5 million (up 19% year-over-year); nine months: $9.6 million (up 16%).

• Gross margin for Q3 2025 was 54%, down from 56% in Q3 2024, with gross profit at $1.9 million.

• Operating expenses rose to $9.9 million for Q3 2025, mainly due to R&D and G&A costs.

• Net loss for Q3 2025 was $7.9 million, compared to $5.8 million in Q3 2024.

• Cash and equivalents totaled $17.8 million as of September 30, 2025, boosted by $23.4 million in IPO proceeds.

Outlook and guidance

• FDA submission for AI-enabled CapsoCam Plus expected by year-end 2025, with clearance and commercialization anticipated in the second half of 2026.

• CapsoCam Colon Gen-2 pivotal study underway, with FDA submission targeted for Q2 2026 and potential clearance in Q4 2026.

• Canon CMOS sensor integration expected in 2027; current pivotal studies will use existing Toshiba sensors with improved optics.

• Management expects continued losses and negative cash flows until further revenue growth and break-even are achieved; existing cash is not sufficient to fund operations for the next 12 months.

• Sales team expansion planned for 2026, with two new territories in large U.S. markets.